As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Cancer Immunology and Immunotherapy”, which are listed below:

1. “Dendritic Cells in Cancer Immunology and Immunotherapy”
by Laura Hato, Angel Vizcay, Iñaki Eguren, José L. Pérez-Gracia, Javier Rodríguez, Jaime Gállego Pérez-Larraya, Pablo Sarobe, Susana Inogés, Ascensión López Díaz de Cerio and Marta Santisteban
Cancers 2023, 16(5), 981; https://doi.org/10.3390/cancers16050981
Available online: https://www.mdpi.com/2072-6694/16/5/981

2. “Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer”
by Julie Daigre, Manuel Martinez-Osuna, Maria Bethke, Larissa Steiner, Vera Dittmer, Katrin Krischer, Cathrin Bleilevens, Janina Brauner, Jens Kopatz, Matthias David Grundmann et al.
Cancers 2023, 16(2), 333; https://doi.org/10.3390/cancers16020333
Available online: https://www.mdpi.com/2072-6694/16/2/333

3. “Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings”
by Daniel Park, Won Jin Jeon, Chieh Yang and Dani Ran Castillo
Cancers 2023, 16(2), 318; https://doi.org/10.3390/cancers16020318
Available online: https://www.mdpi.com/2072-6694/16/2/318

4. “Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives”
by Ilaria Salvato and Antonio Marchini
Cancers 2023, 16(7), 1276; https://doi.org/10.3390/cancers16071276
Available online: https://www.mdpi.com/2072-6694/16/7/1276

5. “Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer”
by Michael Dougan, Long H. Nguyen, Elizabeth I. Buchbinder and Hillard M. Lazarus
Cancers 2023, 16(3), 501; https://doi.org/10.3390/cancers16030501
Available online: https://www.mdpi.com/2072-6694/16/3/501

6. “Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations”
by Philipp Blüm and Sabine Kayser
Cancers 2023, 16(8), 1599; https://doi.org/10.3390/cancers16081599
Available online: https://www.mdpi.com/2072-6694/16/8/1599

7. “Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges”
by Shunzhen Zheng, Siew Wee Chan, Fei Liu, Jun Liu, Pierce Kah Hoe Chow, Han Chong Toh and Wanjin Hong
Cancers 2023, 16(8), 1582; https://doi.org/10.3390/cancers16081582
Available online: https://www.mdpi.com/2072-6694/16/8/1582

8. “The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research”
by Xavier S. Bittman-Soto, Evelyn S. Thomas, Madeline E. Ganshert, Laura L. Mendez-Santacruz and J. Chuck Harrell
Cancers 2023, 16(10), 1859; https://doi.org/10.3390/cancers16101859
Available online: https://www.mdpi.com/2072-6694/16/10/1859

9. “The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma”
by Alexander A. Lekan and Louis M. Weiner
Cancers 2023, 16(3), 559; https://doi.org/10.3390/cancers16030559
Available online: https://www.mdpi.com/2072-6694/16/3/559

10. “Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation”
by Luca Potestio, Massimiliano Scalvenzi, Aimilios Lallas, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Laura Marano and Alessia Villani
Cancers 2023, 16(9), 1732; https://doi.org/10.3390/cancers16091732
Available online: https://www.mdpi.com/2072-6694/16/9/1732

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers. 

Cancers Editorial Office